|Day Low/High||107.39 / 108.95|
|52 Wk Low/High||62.88 / 109.51|
Home builders make up the second-largest allocation in my portfolio, behind biotech.
Drug giants with money to spend and a friendlier regulatory environment should spur deals.
Overall, this is still a good environment for stock picking.
They're striking while the iron is hottest to raise money, reduce debt.
That may be the best way to get through the notorious month of August.
All of these add up to a level of insecurity on the part of sidelined money.
A sharp selloff in crude kept stocks mostly in the red, though optimism ahead of Friday's jobs reports kept losses to a minimum on Thursday.
Biotech company BioMarin Pharmacuetical's shares are moving sharply higher on heavy volume in Friday's session.
Good morning -- Bret Jensen here! As always, it's good to be standing in for Doug Kass. It looks like the rollercoaster in the market will continue today. We had a nice rally on Wednesday, followed by a deep decline yesterday. And this morning, the ...
TheStreet’s Action Alerts PLUS Portfolio Manager Jim Cramer is keeping an eye on shares of BioMarin Pharmaceutical.
BMRN could re-base in the weeks and months ahead as downside looks limited.
The convertible bond market has been fairly flat in 2015, closely following the slim returns seen in equities.
Also, Pfizer-Allergan deal clears another hurdle.
Which means interest rate hikes are being built into prices.
The bulls can show them around the place.
Jim Cramer answers viewers' Twitter questions from the floor of the New York Stock Exchange.
Coal and renewables could both react as political and legal battles ensue.
BioMarin's chart has a well-defined uptrend line and shows great relative strength.
Sector may not be as bulletproof as we thought.